Elevated PABPC4 expression in human prostate cancer tissues predicts adverse clinical outcomes

Authors:
  • XSXianqi Shen
    Xianqi Shen
  • ZLZijian Li
    Zijian Li
  • YSYuchuan Shi
    Yuchuan Shi
  • ZZZenghui Zhou
    Zenghui Zhou
  • YWYan Wang
    Yan Wang
  • MQMin Qu
    Min Qu

Abstract
Background: Poly(A) binding protein cytoplasmic 4 (PABPC4) has been regarded as a prognostic marker in many malignancies. In this study, we evaluated PABPC4 expression at both messenger ribonucleic acid (mRNA) and protein levels. The prognostic value of PABPC4 in patients with prostate cancer (PCa) was also investigated. Methods: The Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) database, our analysis of Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA), and 65 pairs of ribonucleic acid (RNA) sequencing data from our center were employed to detect the expression of PABPC4 in PCa tissues. Tissue microarrays (TMAs) were utilized to detect the expression of the PABPC4 protein, and survival analysis as well as risk factor analysis were conducted. Results: In the 65 pairs of sequencing data, the expression of PABPC4 in tumor tissues was significantly higher than that in paired adjacent tissues (PConclusions: Our study demonstrated that PABPC4 was overexpressed at mRNA and protein levels in PCa. We found that patients with high PABPC4 expression had a shorter biochemical recurrence (BCR)-free survival and OS, showing its value as a prognostic biomarker in patients with PCa.

This publication has 22 references indexed in Scilit: